Overview

Venetoclax and Decitabin Based Conditioning Regimen Followed With Post-HSCT Decitabin Maintenance Therapy in TP53 Mutant AML/MDS Patients

Status:
Recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
This study aims to evaluate the effectiveness and safety of Venetoclax and Decitabin based conditioning regimen followed with post-HSCT Decitabin maintenance therapy in TP53 mutant AML/MDS Patients.
Phase:
Early Phase 1
Details
Lead Sponsor:
Zhejiang University